Comparison of trimodal therapy versus radical cystectomy for each stage of muscle-invasive bladder cancer

doi:10.4103/UROS.UROS_8_21

CNU IR > Pharmacy and Science > Dept. of Biotechnology (including master's program) > Periodical Articles > Item 310902800/34353

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34353

Title:	Comparison of trimodal therapy versus radical cystectomy for each stage of muscle-invasive bladder cancer
Authors:	Tseng, Wen-Hsin Huang, Steven K. Liu, Chien-Liang Kuo, Jinn-Rung Hun, Shun-Hsing Chen, Chun-Hao Su, Chia-Cheng Wang, Jhih-Cheng Lee, Kau-Han Hsieh, Kun-Lin Chiu, Allen W.
Contributors:	Chi Mei Med Ctr, Div Urol, Dept Surg Chia Nan Univ Pharm & Sci Chi Mei Med Ctr, Div Neurosurg, Dept Surg Chi Mei Hosp, Div Urol, Dept Surg Mackay Mem Hosp, Dept Urol Natl Yang Ming Univ, Sch Med
Keywords:	Muscle-invasive bladder cancer radical cystectomy trimodal therapy
Date:	2021
Issue Date:	2023-11-11 11:46:19 (UTC+8)
Publisher:	WOLTERS KLUWER MEDKNOW PUBLICATIONS
Abstract:	Purpose: Radical cystectomy (RC) has long been the standard of care for the management of muscle-invasive bladder cancer (MIBC). However, an increasing trend of bladder-sparing trimodal therapy (TMT) using maximal transurethral resection of bladder tumor, followed by radiation therapy (RT) with concomitant radiosensitizing chemotherapy, has been advocated. We compared the differences regarding long-term oncological outcomes between patients who accepted RC or TMT for MIBC. Materials and Methods: Between January 2012 and December 2018, 207 patients were diagnosed with MIBC at our center. We excluded patients with metastasis disease, received other treatments, and lost to follow-up. The patients were categorized into Group 1 (TMT) and Group 2 (RC). Both the groups with each tumor stage were compared for disease-free survival (DFS) and overall survival (OS) rates, and the risk factors for recurrence and survival were assessed. Results: In total, 58 (48.7%) patients in Group 1 underwent TMT and 61 (51.3%) patients in Group 2 underwent RC. The mean follow-up was 39.8 months. The 3-year DFS rates were 44.1% and 69.7% for Groups 1 and 2, respectively (P = 0.003). The 3-year OS rates were 61.7% and 72.5% for Groups 1 and 2, respectively (P = 0.226). We also analyzed the DFS with each stage, and the results showed a lower DFS rate for T2 and N0 stages. Conclusion: There was no significant survival benefit for MIBC with either RC or TMT. However, RC is associated with better outcome of DFS rate, especially for patients with early stages of MIBC in stages T2 and N0.
Relation:	UROL SCI, v.32, n.4, pp.164-170
Appears in Collections:	[Dept. of Biotechnology (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	159	View/Open
UROS.UROS_8_21.pdf		1075Kb	Adobe PDF	72	View/Open

Loading...